Longeveron (LGVN) Change in Account Payables (2020 - 2026)
Longeveron (LGVN) recorded quarterly Change in Account Payables of -$130000.0 in Q1 2026, up 80.18% quarter-over-quarter from -$656000.0 in Q4 2025, and down 148.69% on a YoY basis from $267000.0 in Q1 2025.
Longeveron (LGVN) Change in Account Payables (2020 - 2026) Analysis & Trends
Longeveron's Change in Account Payables history runs 7 years deep, the most recent figure standing at -$130000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 148.69% year-over-year to -$130000.0; the TTM figure through Mar 2026 stood at -$72000.0 (up 93.47% YoY), while the FY2025 annual figure was $325000.0, up 160.19% from the prior year.
- Change in Account Payables was -$130000.0 for Q1 2026 at Longeveron, up from -$656000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.2 million in Q2 2023 to a low of -$1.3 million in Q1 2023.
- Historically, Change in Account Payables has averaged -$20705.9 across 5 years, with a median of -$7000.0 in 2022.
- Biggest YoY gain for Change in Account Payables was 631.2% in 2023; the steepest drop was 18385.71% in 2023.
- A 5-year view of Change in Account Payables shows it stood at $1.1 million in 2022, then tumbled by 116.65% to -$191000.0 in 2023, then slumped by 312.57% to -$788000.0 in 2024, then advanced by 16.75% to -$656000.0 in 2025, then soared by 80.18% to -$130000.0 in 2026.
- The last three Change in Account Payables figures came in at -$130000.0 (Q1 2026), -$656000.0 (Q4 2025), and $380000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | -130,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -130,000.00 |
| Mar 31, 2026 | -130,000.00 |
| Dec 31, 2025 | -656,000.00 |
| Dec 31, 2025 | -656,000.00 |
| Sep 30, 2025 | 380,000.00 |
| Sep 30, 2025 | 380,000.00 |
| Jun 30, 2025 | 334,000.00 |
| Jun 30, 2025 | 334,000.00 |
| Mar 31, 2025 | 267,000.00 |
| Mar 31, 2025 | 267,000.00 |
| Dec 31, 2024 | -788,000.00 |
| Dec 31, 2024 | -788,000.00 |
| Sep 30, 2024 | 286,000.00 |
| Sep 30, 2024 | 286,000.00 |
| Jun 30, 2024 | -867,000.00 |
| Jun 30, 2024 | -867,000.00 |
| Mar 31, 2024 | 829,000.00 |
| Mar 31, 2024 | 829,000.00 |
| Dec 31, 2023 | -191,000.00 |
| Dec 31, 2023 | -191,000.00 |